IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
H. Liu, H. Y. Teo, Y. Song, K. S. M. Yong, Y. Liu, Y. Mei, Z. B. Hanafi, Y. Zhu, N. R. J. Gascoigne, Q. Chen
This study shows that pre-activating γδT cells with IL-12/18/21 enhances their anti-tumor activity and overcomes resistance to anti-PD-L1 therapy in mouse models.
bioRxiv · Aug 11, 2022 · PreprintImmunology